PCSK9-inhibitor less frequently administered may be effective treatment option
Prof. Eli M. Roth (University of Cincinatti, Ohio, USA)
Recorded at ISA2015, Amsterdam, The Netherlands on May 24-26, 2015
ISA2015 | Clinical Breakthroughs The ODYSSEY CHOICE I evaluated the efficacy of PCSK9-inhibitor alirocumab given once every four weeks instead of every two weeks. Prof. Eli Roth considers this dosing scheme a good option for patients who prefer monthly injections.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.